Clinical trials: Depression / Major Depressive Disorder
Bipolar Depression
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
The main goal of this study is to help answer the following research question(s) and not to treat the child's illness. Can this study drug make children with bipolar depression feel better? Does this study drug work better than a…
- Trial name
- NCT00844857
- Testing
- Olanzapine Fluoxetine Combination (OFC)
- Where
- 7 sites in United States, Russia
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Alcohol Use Disorder
STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse
The purpose of this study is to determine if having an alcohol use disorder affects recovery from depression, and also whether recovery from depression in patients who have alcohol use disorders is also accompanied by improvement…
- Trial name
- NCT00369746
- Testing
- citalopram
- Where
- United States
- Volunteers
- 674 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 8-week acute treatment.
- Trial name
- NCT00694304
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 535 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Major
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and…
- Trial name
- VENTURA-LT (NCT05518149)
- Testing
- Aticaprant
- Where
- 234 sites in United States, Argentina and 19 more
- Volunteers
- 871 people
- Sponsor
- Janssen Research & Development, LLC
Major Depression, Irritable Bowel Syndrome
Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression
This study will evaluate the efficacy of duloxetine in reducing depressive symptoms, abdominal pain, and other symptoms of Irritable Bowel Syndrome (IRS) in a population of outpatients with Major Depressive Disorder MDD and…
- Trial name
- IBS-MDD (NCT01754493)
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression
This study will compare the effect of three transcranial photobiomodulation (t-PBM) doses (high, middle, and low irradiance) to sham t-PBM on PFC CBF as assessed with fMRI (BOLD) in this multi-center, phase I, double-blinded…
- Trial name
- TRIADE (NCT04366258)
- Testing
- Transcranial Photobiomodulator
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- NYU Langone Health
Major Depressive Disorder
Evaluation of a Mental Health Physician Support Program in Nova Scotia
The aim of this study is to test the program's effectiveness in a primary care setting in reducing stigma among medical personnel, increasing the comfort level of physicians and staff in providing care to those living with mental…
- Trial name
- NCT01975948
- Testing
- Mental Health Practice Support Program, Treatment as Usual
- Where
- Canada
- Volunteers
- 285 people
- Sponsor
- Nova Scotia Health Authority
Depression
iTBS for Adolescent Depression: An Open Label Study Evaluating Safety and Efficacy of Treatment
This is an open label, pilot, feasibility study evaluating effects of Intermittent Theta Burst Transcranial Magnetic Stimulation (iTBS) on 5 eligible adolescents for the treatment of depression.
- Trial name
- NCT04485455
- Testing
- iTBS Device/Motor Threshold Coil, iTBS Device/Treatment Coil
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
A Novel Cognitive Remediation Intervention Targeting Poor Decision-making and Depression in Veterans at High Risk for Suicide: A Safe, Telehealth Approach During the COVID-19 Pandemic
Despite large-scale, nationwide efforts to better address suicidal behavior in Veterans at high risk, the development of interventions that target some of the key risk factors associated with suicide remains limited.
- Trial name
- CogRemVet (NCT04952532)
- Testing
- Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Depression and Suicide
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention
This is a rater-blinded, randomized controlled trial. All patients will receive esketamine for treatment of Major Depression with Suicidal Ideation (MDSI).
- Trial name
- ENDURE (NCT04760652)
- Testing
- Cognitive Behavioral Therapy CBT, TAU
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Yale University
Major Depressive Disorder, Depression
HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2
This randomized two-arm intervention trial administers 8 weekly cognitive behavioral therapy (CBT) sessions and 4 bi-weekly active whole-body hyperthermia (active WBH) sessions or 4 bi-weekly sham WBH sessions to adults aged 18…
- Trial name
- HEATBED2 (NCT05708976)
- Testing
- Cognitive Behavioral Therapy (CBT), Active Whole-Body Hyperthermia (Active WBH)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder
Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for eight weeks will be associated with significant increases in frontal lobe phosphocreatine and beta-nucleoside triphosphate (β-NTP)…
- Trial name
- NCT02134808
- Testing
- Creatine
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Treatment Resistant Depression
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of oral CERC-501 for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
- Trial name
- RAPID KOR (NCT01913535)
- Testing
- CERC-501
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Focal Electroconvulsive Therapy for Depression
This pilot, open label investigation evaluates the safety and efficacy of a new form of electroconvulsive therapy (ECT). Both the efficacy and adverse cognitive effects of ECT are highly contingent on the intracerebral current…
- Trial name
- FEAST (NCT01589315)
- Testing
- focal ECT
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Medical University of South Carolina
Bipolar Disorder, Depression
Early Detection and Prevention of Mood Disorders in Children of Parents With Bipolar Disorder
This study will develop strategies for early detection and prevention of mood disorders and associated impairment in adolescent children of parents with bipolar disorder.
- Trial name
- NCT00338806
- Testing
- Interpersonal psychotherapy for prevention with adolescents, Educational clinical monitoring
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Trial of Levomilnacipran in Geriatric Depression
The purpose of this study is to examine the effects of levomilnacipran (FETZIMA) compared to placebo for the treatment of depression in older adults.
- Trial name
- LMIL (NCT02466958)
- Testing
- levomilnacipran
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder
Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
The primary purpose of your participation in this study is to help answer the following research question: Whether 12-week administration of EMSAM (selegiline transdermal system) is safe and effective for the treatment of…
- Trial name
- NCT00531947
- Testing
- Selegiline Transdermal System
- Where
- 20 sites in United States
- Volunteers
- 308 people
- Sponsor
- Somerset Pharmaceuticals
Depressive Disorder, Major
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)
This study will evaluate the efficacy, safety, and tolerability of two doses of rapastinel, 225 milligrams (mg) and 450 mg, compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder…
- Trial name
- NCT02943564
- Testing
- Rapastinel
- Where
- 66 sites in United States
- Volunteers
- 658 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Depressive Disorder, Major
Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
The purpose of this study is to assess the efficacy and safety of multiple doses of vortioxetine, once daily (QD), in participants with major depressive disorder.
- Trial name
- NCT01255787
- Testing
- Vortioxetine
- Where
- 70 sites in Croatia, Finland and 14 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Depression
Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole
We hope to learn how a brain circuit that is important to the understanding of depression, anhedonia and positive affect responds to a novel pharmaceutical treatment for depression and related symptoms.
- Trial name
- NCT01066897
- Testing
- Pramipexole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Stanford University